Expert Interview
Evaluating Travere Therapeutics' FILSPARI for the Treatment of IgA Nephropathy: A Comprehensive Analysis
Ticker(s): TVTXInstitution: Montefiore
- Medical Director, Pediatric Nephrology at Montefiore Health System, Inc., Associate Professor of Pediatrics at the Albert Einstein College of Medicine & Visiting Assistant Professor at Rockefeller University.
- Clinical interests are polycystic kidney disease, lupus nephritis, genetic causes of stone disease, complement pathway defects, immune-mediated renal diseases (autoimmune and secondary immune disorders) and biomarkers of acute kidney injury with a research interest is in lupus nephritis.
- Involved in clinical and translational research studying factors leading to progression to end-stage kidney disease, including fibrosis and complement-mediated pathways in lupus nephritis.
Can you explain the mechanism of action of FILSPARI and how it differentiates from other treatments available for IgA Nephropathy?
Added By: catalin_adminBased on the PROTECT Study, FILSPARI showed favorable results compared to irbesartan. Can you elaborate on the significance of these findings, especially the eGFR total and chronic slope results?
Added By: catalin_adminThe PROTECT Study highlighted a notable reduction in proteinuria with FILSPARI treatment. How critical is this reduction for patients with IgA Nephropathy, and what potential long-term benefits can be anticipated?
Added By: catalin_adminWhat can you tell us about the safety profile of FILSPARI based on the 110-week treatment data from the PROTECT Study? Were there any notable adverse events or side effects that clinicians should be aware of?
Added By: catalin_adminHow does FILSPARI's efficacy and safety profile compare to other treatments, especially considering the head-to-head study against a maximally tolerated dose of irbesartan?
Added By: catalin_adminIn what ways does FILSPARI address the unmet medical needs in the treatment landscape of IgA Nephropathy?
Added By: catalin_adminGiven the results of the PROTECT Study and the potential FDA approval, how do you see FILSPARI shaping the future treatment paradigm for IgA Nephropathy?
Added By: catalin_adminConsidering the evolving scientific and clinical advancements in nephrology, where does FILSPARI fit into the broader IgA Nephropathy treatment landscape?
Added By: catalin_adminDr. Brad Rovin mentioned that FILSPARI has the potential to become a long-term foundational therapy for IgA Nephropathy. Do you share this sentiment, and if so, why?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
